» Articles » PMID: 22236224

Germline Mutations in HOXB13 and Prostate-cancer Risk

Abstract

Background: Family history is a significant risk factor for prostate cancer, although the molecular basis for this association is poorly understood. Linkage studies have implicated chromosome 17q21-22 as a possible location of a prostate-cancer susceptibility gene.

Methods: We screened more than 200 genes in the 17q21-22 region by sequencing germline DNA from 94 unrelated patients with prostate cancer from families selected for linkage to the candidate region. We tested family members, additional case subjects, and control subjects to characterize the frequency of the identified mutations.

Results: Probands from four families were discovered to have a rare but recurrent mutation (G84E) in HOXB13 (rs138213197), a homeobox transcription factor gene that is important in prostate development. All 18 men with prostate cancer and available DNA in these four families carried the mutation. The carrier rate of the G84E mutation was increased by a factor of approximately 20 in 5083 unrelated subjects of European descent who had prostate cancer, with the mutation found in 72 subjects (1.4%), as compared with 1 in 1401 control subjects (0.1%) (P=8.5x10(-7)). The mutation was significantly more common in men with early-onset, familial prostate cancer (3.1%) than in those with late-onset, nonfamilial prostate cancer (0.6%) (P=2.0x10(-6)).

Conclusions: The novel HOXB13 G84E variant is associated with a significantly increased risk of hereditary prostate cancer. Although the variant accounts for a small fraction of all prostate cancers, this finding has implications for prostate-cancer risk assessment and may provide new mechanistic insights into this common cancer. (Funded by the National Institutes of Health and others.).

Citing Articles

HOXB13 in cancer development: molecular mechanisms and clinical implications.

Zhang J, Li Y, Peng B, Yang X, Chen M, Li Y Front Med. 2025; .

PMID: 40067581 DOI: 10.1007/s11684-024-1119-x.


Assessing the contribution of rare protein-coding germline variants to prostate cancer risk and severity in 37,184 cases.

Mitchell J, Camacho N, Shea P, Stopsack K, Joseph V, Burren O Nat Commun. 2025; 16(1):1779.

PMID: 39971927 PMC: 11839991. DOI: 10.1038/s41467-025-56944-1.


CRISPR screening identifies regulators of enhancer-mediated androgen receptor transcription in advanced prostate cancer.

Xiang R, Lee S, Tyndall C, Bhatia A, Yin J, Singler C Cell Rep. 2025; 44(2):115312.

PMID: 39954255 PMC: 11867844. DOI: 10.1016/j.celrep.2025.115312.


Efficacy of Next-Generation Sequencing in Identifying Genetic Markers for Prostate Cancer Risk.

Alaithan F, Alaithan R, Ahmed T J Pharm Bioallied Sci. 2025; 16(Suppl 4):S3712-S3714.

PMID: 39926850 PMC: 11805145. DOI: 10.4103/jpbs.jpbs_1083_24.


Integrating BRCA testing into routine prostate cancer care: a multidisciplinary approach by SIUrO and other Italian Scientific Societies.

Mammone G, Borghesi S, Borsellino N, Calio A, Ceccarelli R, Cimadamore A BMC Cancer. 2025; 25(1):127.

PMID: 39844131 PMC: 11756108. DOI: 10.1186/s12885-025-13521-5.


References
1.
Siegel R, Ward E, Brawley O, Jemal A . Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 2011; 61(4):212-36. DOI: 10.3322/caac.20121. View

2.
Fukasawa S, Kino M, Kobayashi M, Suzuki H, Komiya A, Imamoto T . Genetic changes in pT2 and pT3 prostate cancer detected by comparative genomic hybridization. Prostate Cancer Prostatic Dis. 2007; 11(3):303-10. DOI: 10.1038/sj.pcan.4501017. View

3.
Thorsteinsdottir U, Kroon E, Jerome L, Blasi F, Sauvageau G . Defining roles for HOX and MEIS1 genes in induction of acute myeloid leukemia. Mol Cell Biol. 2000; 21(1):224-34. PMC: 88796. DOI: 10.1128/MCB.21.1.224-234.2001. View

4.
Lange E, Beebe-Dimmer J, Ray A, Zuhlke K, Ellis J, Wang Y . Genome-wide linkage scan for prostate cancer susceptibility from the University of Michigan Prostate Cancer Genetics Project: suggestive evidence for linkage at 16q23. Prostate. 2008; 69(4):385-91. PMC: 2712837. DOI: 10.1002/pros.20891. View

5.
Edwards S, Campbell C, Flohr P, Shipley J, Giddings I, Te-Poele R . Expression analysis onto microarrays of randomly selected cDNA clones highlights HOXB13 as a marker of human prostate cancer. Br J Cancer. 2004; 92(2):376-81. PMC: 2361840. DOI: 10.1038/sj.bjc.6602261. View